Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,500,950 shares, an increase of 26.3% from the February 26th total of 1,979,996 shares. Based on an average daily volume of 212,578 shares, the short-interest ratio is presently 11.8 days. Currently, 7.0% of the shares of the company are sold short.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ EPRX traded down $0.08 during mid-day trading on Monday, reaching $6.64. 47,124 shares of the stock were exchanged, compared to its average volume of 228,322. The company has a market capitalization of $238.78 million, a P/E ratio of -6.45 and a beta of 1.27. The business’s 50 day moving average is $8.11 and its 200-day moving average is $6.97. Eupraxia Pharmaceuticals has a 1 year low of $2.68 and a 1 year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). Equities analysts predict that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on EPRX shares. HC Wainwright lowered their price target on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen cut Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Finally, Cantor Fitzgerald lifted their price target on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Quadrature Capital Ltd acquired a new stake in shares of Eupraxia Pharmaceuticals in the second quarter valued at about $61,000. TCI Wealth Advisors Inc. acquired a new position in Eupraxia Pharmaceuticals during the third quarter worth about $65,000. Integrated Wealth Concepts LLC purchased a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at about $71,000. Bank of America Corp DE grew its stake in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC acquired a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at about $76,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.